Male carriers of BRCA2 germline pathogenic sequence variants (PSV) experience 2.6-fold higher lifetime risk of prostate cancer and a 7.3–8.6-fold higher risk of developing early-onset (<65 years) prostate cancer1–3. The gene discussed is BRCA2; the disease is prostate cancer.